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ABSTRACT 
 
 
  
ABSTRACT 
BACKGROUND 
Posterior capsular opacification (PCO) is a common complication of 
cataract surgery  with  a  (PCIOL) posterior chamber intraocular lens 
implantation. Its incidence varies from 7% to 31%, by 2 years postoperatively. 
Standard treatment  procedure of  PCO consists of making an opening in the 
central part  of posterior capsule. Nd: YAG laser posterior Capsulotomy is the 
treatment of choice for the PCO.  
            The Nd: YAG lasing medium is a man-made crystal made of 
Neodymium doped yttrium-Aluminium-Garnet. It  is a photo disrupter not a 
photo-coagulator like argon or krypton laser. In laser machines, emitted photons 
are reflected in  highly polished mirrors forcing them to travel back & forth in 
the cavity. When a  photon moves very close to an excited particle, this particle 
will be stimulated to emit a photon which is similar in wavelength,  phase and 
spatial coherence  to the first. This amplification continues, thus increasing the 
number of active photons. 
             The  procedure is non-invasive, relatively safer, less time consuming 
and free from infection  but has been associated with complications, which 
include 
- raised intraocular pressure  
-IOL pitting,  
-cystoid macular oedema and  
- retinal detachment.  
Raised intraocular pressure  remains to be one of the frequent complications of  
Nd: YAG  laser capsulotomy. It is acute but transient. The efficacy of 0.5 % 
Timolol eye drops vs. 0.2% Brimonidine eye drops in monitoring rise in IOP 
following  Nd-YAG  Capsulotomy will be studied. 
 
AIM OF THE STUDY 
A Study to compare the efficacy of 0.5 % Timolol eye drop’s vs. 0.2% 
Brimonidine eye drops in management of rise in Intra Ocular Pressure 
following  neodymium-yttrium aluminium garnet (YAG) capsulotomy for 
Posterior Capsular Opacification. 
 
OBJECTIVES 
1. To measure the rise in IOP following Nd: YAG capsulotomy. 
2. To  measure the effect of 0.5% Timolol in management of rise in IOP 
following Nd: YAG Capsulotomy. 
3. To measure the effect of 0.2% Brimonide in management of rise in IOP 
following Nd: YAG Capsulotomy. 
4. To compare the efficacy of 0.5 % Timolol eye drop’s vs. 0.2% Brimonidine 
eye drops management of rise in IOP following Nd: YAG Capsulotomy 
 
MATERIALS AND METHODS 
STUDY DESIGN 
 Open-label, Randomized hospital based study. 
SETTING 
The study was conducted in the Ophthalmology Department of Coimbatore 
Medical College Hospital which is a tertiary care Hospital and Major reference 
centre getting adequate number of PCO cases. 
DURATION OF STUDY  
From August 2013 – July 2014 
STUDY POPULATION 
 Patients in the age group between 40 to 70 years having posterior capsular 
opacification visiting the Out Patient in the Department of Ophthalmology of 
Coimbatore  Medical College Hospital. 
CASE SELECTION 
Patients who are pseudophakes with posterior chamber IOLs having poor vision 
due to PCO  who have had a cataract surgery more than 6 months. 
1. Informed consent was taken from patients undergoing Nd: YAG laser 
posterior capsulotomy. 
2. Subjects consenting  to take  part in the study were  matched in terms 
of age and sex.  
3. An increase in IOP of  >5 mmHg from the baseline (prelaser 
capsulotomy)  after Nd: YAG  capsulotomy was termed as having 
‘raised IOP’. 
4. Energy used in this procedure was  termed  as ‘low energy’ if it was 
less than 30 mJ and ‘high energy’ if it was > 30 mJ. 
Sample Size –100 patients with PCO( Posterior Capsular Opacification ) was 
studied for post ND: YAG laser rise in IOP. The patient not having any organic 
cause of decreased vision and who have completed at least 6  months after 
cataract surgery were selected. 
50 of these patients were given 1 drop of 0.5% Timolol eye drops 1 hour before 
the procedure and I drop  after  the procedure and were advised to use  0.5 % 
Timolol eye drops twice a day for the next 7 days  . The remaining 50 of these 
patients are given 1 drop of  0.2% Brimonidine eye drops 1 hour before the 
procedure and I drop after the procedure and were  advised to use  0.2% 
Brimonidine eye drops twice a day for the next 7 days . 
RESULT AND CONCLUSION 
In the study   “Comparing  efficacy  of  Topical  Anti Glaucoma  Medication  in  
monitoring  rise  in  IOP  following  Nd-YAG  Capsulotomy.” had  the  
following outcomes. 
1. The initial transient rise in IOP following ND YAG Capsulotomy in patients 
of the brimonidine group was significantly less than the Timolol group. 
2, Normalisation of  IOP  was same  in both the Timolol  Group  and 
Brimonidine group . 
3. Even though after 4 hours of procedure IOP in both groups normalised the 
initial difference in transient rise of IOP in both the groups was statistically 
significant. ( IOP  rise was higher  with Timolol group than  Brimonidine 
group). 
4. The better control of this initial slight and transient  rise  of IOP is more 
important in known cases of  Pre existing Glaucoma. 
5. This is of greater  significance  particularly in patients with Pre existing 
Glaucoma with compromised optic nerve head  perfusion  where  even  a 
transient  and slight  elevation of  IOP  can  further  jeopardise the  already  
compromise the optic nerve function. 
 
6 .Hence in  our study it was found that Topical Brimonidine had a better 
control in the initial transient rise of IOP following ND YAG 
Capsulotomy  hence it can be taken as a valid point of consideration 
when treating PCO in a case with pre-existing Glaucoma .  
 
KEY WORDS 
Nd YAG  –   neodymium-doped  yttrium  aluminium  garnet 
PCO – posterior  capsular  opacification. 
 
 
